AUS
NZ
UK
CA
USA
IND
Futura Medical PLC (LSE:FUM) has announced a significant milestone in its financial performance for the first half of 2024, marking its first profit of £1 million on revenues of £7 million. The company closed the period with a strong balance sheet, holding £3.9 million in cash.
The positive financial results come as Futura prepares for the upcoming U.S. launch of its erectile dysfunction gel, Eroxon, in partnership with Haleon, a spinoff from GSK. This gel is noted for its rapid onset of action, providing users with an erection within ten minutes. Eroxon is already available for pre-order in the U.S. with deliveries scheduled for October and subsequent availability in stores. This development triggers the next milestone payment from Haleon, mirroring the scale of previous payments.
CEO James Barder highlighted the achievement, stating, “It is a significant milestone to be able to announce our first profit, a year after the initial pilot launch of Eroxon, and well ahead of market expectations.” Barder emphasized that this profit marks the beginning of Eroxon's potential, positioning it as a key player in the underserved sexual health market.
In addition to its European successes in countries such as France, Italy, and Spain, Futura Medical is set to further expand its market presence in 2024. To support increasing demand, the company has secured partnerships with two new contract manufacturers to enhance its supply chain and production capacity.
Furthermore, Futura Medical has extended its licensing agreement with Cooper until 2029, ensuring ongoing market access for its products. The company’s strategic steps and financial achievements underscore its commitment to growth and innovation in the healthcare sector.
